Welcome to our dedicated page for Clearmind Medicine Common Shares news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medicine Common Shares stock.
Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) is a clinical-stage psychedelic pharmaceutical biotech company dedicated to the discovery and development of innovative psychedelic-derived therapeutics. The company focuses on addressing widespread and under-treated health issues, particularly alcohol use disorder (AUD).
Currently, Clearmind's flagship compound, CMND-100, is in the spotlight. This MEAI-based (5-methoxy-2-aminoindane) formula has shown promising pre-clinical results in disrupting binge drinking behaviors without inducing hallucinations. The Israeli Ministry of Health has recently approved a Phase I/IIa clinical trial for CMND-100, marking a significant milestone in its development.
Clearmind's intellectual property portfolio is robust and growing, comprising eighteen patent families and 27 granted patents. Recent developments include nine new patent applications filed with the USPTO, highlighting compositions for treating alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. These efforts reflect the company's commitment to expanding and protecting its IP assets.
Collaborations play a crucial role in Clearmind's strategy. The company has entered exclusive licensing agreements with institutions such as the Hebrew University of Jerusalem, further enriching its portfolio with generation 3.0 psychedelic compounds aimed at treating addiction and mental health disorders. Additionally, Clearmind has initiated a groundbreaking partnership with Yissum Research Development Company for PTSD treatments.
Another key project is Clearmind's proprietary MEAI-based alcohol substitute beverage program. This ethanol-free alternative aligns with the growing global trend towards no- and low-alcohol consumption, offering a health-focused option for consumers.
Clearmind Medicine Inc. continues to execute its intellectual property and development strategies, positioning itself at the forefront of psychedelic-based medical treatments. The company’s shares are traded on Nasdaq under the symbol 'CMND' and on the Frankfurt Stock Exchange under 'CWY0'.
For more information, please visit their official website at www.clearmindmedicine.com or contact Investor Relations at invest@clearmindmedicine.com.
Clearmind Medicine Inc. (NASDAQ: CMND) has submitted an Investigational New Drug (IND) application to the FDA for its first-in-human Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial aims to start in Q2 2023 if approved. CMND-100's active ingredient, MEAI, is a novel psychoactive molecule that shows promise in reducing alcohol consumption through interactions with serotonergic and adrenergic receptors. The treatment addresses a significant healthcare issue, with 28 million adults in the U.S. facing AUD, leading to substantial economic losses.
Clearmind Medicine Inc. (Nasdaq: CMND) has appointed Professor Henry R. Kranzler, M.D., to its Scientific Advisory Board. Professor Kranzler, a leading expert in addiction medicine, serves at the University of Pennsylvania and has extensive experience in the genetics and pharmacological treatment of substance dependence. His appointment is seen as a strategic move to enhance Clearmind's development of psychedelic-derived therapeutics for alcohol use disorder and other substance use treatments. Clearmind is focused on addressing major health issues through innovative drug candidates, bolstered by its portfolio of 13 patent families.
Clearmind Medicine Inc. (NASDAQ: CMND) announced the submission of three provisional patent applications to the USPTO for unique psychedelic-based compounds in collaboration with SciSparc Ltd. The applications focus on combinations of MDMA, Ibogaine, and Ketamine with Palmitoylethanolamide (PEA), aiming to expand their intellectual property (IP) portfolio within the psychedelic space. Clearmind currently holds 29 patents in 13 families, with plans for further innovation in mental health treatments. CEO Dr. Adi Zuloff-Shani emphasized the goal of addressing unmet patient needs through innovative medicine.
Clearmind Medicine Inc. (NASDAQ: CMND) has filed three provisional patent applications with the USPTO in collaboration with SciSparc Ltd. to develop innovative psychedelic-based treatments. The patents encompass combinations of LSD, psilocybin, DMT, and the active ingredient of CannAmide™, aimed at enhancing efficacy and safety for mental health therapies. Clearmind boasts 23 patents across seven families, positioning itself strongly in the psychedelic sector. The company's strategy focuses on providing safer, more effective treatments for mental health disorders and expanding their intellectual property portfolio.
Clearmind Medicine Inc. (NASDAQ: CMND) will attend the 2023 OurCrowd Global Investor Summit on February 15 in Jerusalem. CEO Dr. Adi Zuloff-Shani will discuss the company’s recent Nasdaq IPO with David Huberman from Greenberg Traurig. This session, titled “IPOs in a Down Market,” aims to provide insights into the IPO process and the challenges faced in the current economic climate. Clearmind focuses on developing psychedelic-derived therapeutics to address significant health issues, holding seven patent families, and aims to expand its intellectual property portfolio.
Clearmind Medicine Inc. (NASDAQ: CMND) will host a virtual investor conference titled “Psychedelics for Obesity” on February 28, 2023, at 8:30 AM EST. The event will highlight recent positive pre-clinical results for its drug candidate MEAI, aimed at treating obesity and metabolic syndrome. Professor Joseph Tam, leading the study from Hebrew University's Institute for Drug Research, will discuss these findings. CEO Dr. Adi Zuloff-Shani will outline the company's achievements and future goals. Clearmind focuses on developing psychedelic-derived therapeutics for significant health issues and is listed on NASDAQ under CMND.
Clearmind Medicine Inc. (NASDAQ: CMND) has announced promising results from a pre-clinical trial involving 2-Fluorodeschloroketamine (2-FDCK), an analogue of Ketamine, aimed at treating Major Depressive Disorder (MDD). Conducted in collaboration with Bar-Ilan University, the trial evaluated the effects of 2-FDCK on rodent models of depression. Results indicated superior efficacy of 2-FDCK over Ketamine, especially in chronic treatment settings. Clearmind's CEO highlighted the significance of these findings for patients with treatment-resistant depression, emphasizing the company's commitment to developing innovative psychedelic-derived therapeutics.
Clearmind Medicine (NASDAQ: CMND) announced its participation at Isranalytica 2023, a leading analytical chemistry conference. Professor Joseph Tam presented promising pre-clinical trial results for MEAI, its drug candidate aimed at treating obesity and metabolic syndrome. Tam's presentation titled "The Psychoactive Drug 5-Methoxy-2-aminoindane (MEAI) Ameliorates Obesity and its Metabolic Complications" showcased the drug's efficacy. CEO Dr. Adi Zuloff-Shani emphasized the importance of raising awareness within the scientific community to support future clinical programs. Clearmind focuses on developing psychedelic-derived therapeutics for untreated health issues.
Clearmind Medicine Inc. (Nasdaq, CSE: CMND) recently announced the successful completion of two innovative drug-discovery projects at the Hebrew University. These projects focus on developing novel psychedelic compounds aimed at enhancing therapeutic effects for under-treated health issues. Led by esteemed professors, the initiatives involved synthesizing synthetic molecules and evaluating psychedelic analogues for efficacy and safety. The promising results from these projects will allow Clearmind and Yissum to advance multiple new patent applications, expanding the company’s intellectual property portfolio. The firm remains committed to its mission of providing innovative solutions for mental health challenges.
Clearmind Medicine Inc. (CMND) announced promising pre-clinical results for its drug candidate MEAI, showing potential in treating substance addiction without affecting natural reward processes. Conducted at Bar Ilan University, the in-vivo studies revealed that MEAI, at a dose of 5mg/kg, significantly decreased cocaine craving, marking it as a potential first-of-its-kind treatment for cocaine addiction. The researchers confirmed that MEAI allows for the maintenance of natural rewards, distinguishing it from traditional addiction treatments. CEO Dr. Adi Zuloff-Shani emphasized the importance of these results in addressing cocaine addiction, which currently lacks dedicated therapies.
FAQ
What is the current stock price of Clearmind Medicine Common Shares (CMND)?
What is the market cap of Clearmind Medicine Common Shares (CMND)?
What is Clearmind Medicine Inc.'s primary area of focus?
What is CMND-100?
What recent clinical developments has Clearmind made?
What are the key features of Clearmind's intellectual property portfolio?
What strategic collaborations has Clearmind entered into?
What is Clearmind's MEAI-based alcohol substitute beverage program?
Where are Clearmind's shares traded?
How can I contact Clearmind Medicine Inc. for more information?
What is Clearmind's approach to intellectual property?
How does Clearmind ensure the safety of its novel compounds?
